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Background: It is unclear whether atrial fibrillation (AF) catheter ablation (AFCA) improves
the left ventricular (LV) diastolic function. We evaluated the 1-year change in the H2FPEF
score, which reflects the degree of LV diastolic function, after AFCA among patients with
a normal LV systolic function.
Methods and Results: We included 1,471 patients (30.7% female, median age
60 years, paroxysmal-type AF 68.6%) who had available H2FPEF scores at baseline
and at 1-year after AFCA to evaluate the 1-year change in the H2FPEF score
(1H2FPEF score[1−yr]) after AFCA. Baseline high H2FPEF scores (≥6) were independently
associated with the female sex, left atrium (LA) diameter, LV mass index, pericardial fat
volume, and a low estimated glomerular filtration rate. One year after AFCA, decreased
1H2FPEF scores[1−yr] were associated with baseline H2FPEF scores of ≥6 [OR, 4.19
(95% CI, 2.88–6.11), p < 0.001], no diabetes [OR, 0.60 (95% CI, 0.37–0.98), p =
0.04], and lower pericardial fat volume [OR, 0.99 (95% CI, 0.99–1.00), p = 0.003].
Increased 1H2FPEF scores[1−yr] were associated with a baseline H2FPEF score of
<6 [OR, 3.54 (95% CI, 2.08–6.04), p < 0.001] and sustained AF after a recurrence
within 1 year [SustainAF[1−yr]; OR, 1.89 (95% CI, 1.01–3.54), p = 0.048]. Throughout
a 56-month median follow-up, an increased 1H2FPEF score[1−yr] resulted in a poorer
rhythm outcome of AFCA (at 1 year, log-rank p = 0.003; long-term, log-rank p = 0.010).
Conclusions: AFCA appears to improve LV diastolic dysfunction. However,
SustainAF[1−yr] may contribute to worsening LV diastolic dysfunction, and it was shown
by increased 1H2FPEF scores[1−yr], which was independently associated with higher
risk of AF recurrence rate after AFCA.
Clinical Trial Registration: ClinicalTrials.gov Identifier: NCT02138695.
Keywords: atrial fibrillation, catheter ablation, left venticular diastolic dysfunction, recurrent event, risk score
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INTRODUCTION
Atrial fibrillation (AF) and underlying heart failure (HF) have
been emerging topics of importance in the field of cardiovascular
disease over the past 3 decades and frequently overlap (1, 2).
Specifically, AF has been shown to follow HF with preserved
ejection fraction (HFpEF) more frequently than HF with
reduced ejection fraction (HFrEF) due to the differences in the
left ventricular (LV) diastolic dysfunction and the left atrial
(LA) remodeling process (2, 3). Prior studies have shown
improvements in the LV systolic function (4), performance and
quality of life (5), and mortality (6) after AF catheter ablation
(AFCA) in HFrEF patients, suggesting that a reduction in AF
may be sufficient for a clinical benefit. Nevertheless, there are
no specific recommendations for the management of AF in
HFpEF patients, and data regarding the efficacy of AFCA in
patients with a normal LV systolic function and LV diastolic
dysfunction are relatively limited. Although there have been
a few studies reporting an improvement in the LV diastolic
function after AFCA by maintaining sinus rhythm (7, 8), they
adopted conventional approaches that used mainly symptoms
and the LV ejection fraction (LVEF) for the diagnosis of HFpEF
with various diagnostic accuracies (9). Recently, a novel scoring
system has been developed, the H2FPEF score (10), which can
estimate the probability of the underlying HFpEF through six
clinical and echocardiographic characteristics, and can be feasibly
applied in clinical practice. The aim of this study was to better
understand the factors by which LV diastolic function worsens or
improves after AF rhythm control by AFCA. In this study, we
used the H2FPEF score at two time points, before and 1 year
after the AFCA. We aimed to compare the cardiac structural
and functional changes within a year and to evaluate the rhythm




The study protocol adhered to the Declaration of Helsinki
and was approved by the institutional review board of the
Yonsei University Health system. All patients provided written
informed consent for inclusion in the Yonsei AF Ablation
Cohort Database (ClinicalTrials.gov Identifier: NCT02138695).
From January 2009 to September 2019, 1,471 patients with
a diagnosis of AF and a normal LVEF were identified
as having clinical and echocardiographic information for
the calculation of the H2FPEF score before AFCA and 1
year after AFCA. All patients underwent AFCA, and the
indications for the AFCA complied with the latest guidelines
(11). The exclusion criteria for the study were as follows:
(1) a reduced LVEF, defined as <50%; (2) a follow-up
duration <12 months; and (3) a repeat ablation within a
year (Figure 1).
Abbreviations: 1H2FPEF score[1−yr], 1-year change in the H2FPEF score;
SustainAF[1−yr], sustained AF after a recurrence within a year.
Calculating the H2FPEF Score at Baseline
and 1 Year After the Atrial Fibrillation
Catheter Ablation
The H2FPEF score has six domains based on clinical and
echocardiographic values: heaviness (body mass index >30
kg/m2, 2 points), hypertension (on two or more antihypertensive
medicines, 1 point), atrial fibrillation (paroxysmal or persistent,
3 points), pulmonary hypertension (Doppler echocardiographic
estimated pulmonary artery systolic pressure >35 mmHg,
1 point), elderly status (age >60 years, 1 point), and
filling pressure (Doppler echocardiographic E/Em > 9, 1
point). The baseline H2FPEF scores were obtained within 3
months prior to the AFCA, and the 1-year H2FPEF scores




Transthoracic echocardiography was conducted in all patients
using commercially available devices (Vivid 7 or Vivid E9
from GE Healthcare, Chicago, IL, USA, or iE 33 from
Philips, Amsterdam, the Netherlands) as recommended by the
American Society of Echocardiography (12). Standard images
were obtained in the parasternal and apical views through two-
dimensional (2D), Doppler, and M-mode imaging, including
the LA anteroposterior diameter and the LV end-systolic and
end-diastolic dimensions (LVESD and LVEDD). The early
Doppler mitral inflow (E) was recorded using pulsed waves
from the apical window, with a 1- to 3-mm pulsed Doppler
sample volume placed between the tips and mitral leaflets
during diastole. The early diastolic mitral annular velocity (Em)
was recorded as the peak early diastolic tissue velocity using
color Doppler tissue imaging of the septal mitral annulus.
The ratio of the early diastolic mitral inflow velocity to the
early diastolic mitral annular velocity (E/Em) was calculated.
Tricuspid regurgitation (TR) and estimated right atrial (RA)
pressure were evaluated using the recommended methods, and
the right ventricular systolic pressure (RVSP) was calculated as
4 × (TR jet)2 + estimated RA pressure (13). The initial and 1
year after AFCA, the echocardiographies used to estimate the
H2FPEF scores were those performed during an elective visit on
stable medication.
Three-dimensional spiral computed tomography
(CT) (64-channel, Light Speed Volume CT from GE
Healthcare, Chicago, IL, USA, or Brilliance 63 from
Philips, Amsterdam, the Netherlands) was performed in all
patients, and the scans were analyzed using an imaging-
processing workstation (Aquarius; TeraRecon, Inc., Foster
City, CA, USA). The LA volume and pericardial fat




Intracardiac electrograms were obtained using the Prucka
CardioLabTM Electrophysiology system (GEHealthcare, Chicago,
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FIGURE 1 | Screening and study flowchart of the patient selection. AF, atrial fibrillation; AFCA, atrial fibrillation catheter ablation; LV, left ventricular.
IL, USA). A 3D electro-anatomical map (Ensite NavX; Abbott
Laboratories, Chicago, IL, USA; CARTO3; Johnson & Johnson
Inc., USA) was generated using a circumferential pulmonary
vein-mapping catheter through a long sheath (Schwartz left
1; Abbott Laboratories, Chicago, IL, USA) and by merging
the 3D geometry generated by the electroanatomic mapping
system with the corresponding 3D spiral CT images. Left atrium
electrogram voltage maps were generated during high right atrial
pacing at 500ms to prevent rate-dependent activation changes
and by measuring mean peak-to-peak voltage as previously
described (16). All patients underwent a de novo procedure with a
circumferential pulmonary vein isolation (CPVI). The endpoint
of the CPVI was the electric isolation of the PV potentials and
bidirectional block of the PVs. We tested whether there was an
immediate recurrence of AF within 10min after cardioversion
with an isoproterenol infusion (5–20 µg/min depending on
the ß-blocker used with a target sinus heart rate of 120 bpm)
to find extra-PV foci triggers, then confirmed successful CPVI
30min after the initial isolation. Extra-PV foci triggers under an
isoproterenol infusion were ablated as much as possible if they
were consistent and reproducible. Then, we ended the de novo
procedure. The detailed procedural techniques and strategies for
the AFCA have been presented in our previous studies (17, 18).
Post-ablation Management and Rhythm
Follow-Up
The patients were discharged without any antiarrhythmic drugs
(AADs) with the exception of those who had symptomatic
frequent atrial premature beats, non-sustained atrial tachycardia
(AT), early recurrence of AF on telemetry during the admission
period, or recurrent extra-PV foci triggers after the AFCA
procedure (13.7%). The clinical and cardiac rhythm information
was obtained regularly from an outpatient clinic at 1, 3, 6, and 12
months, and every 6 months thereafter (or whenever symptoms
developed). All patients underwent electrocardiogram recordings
at every visit, and 24-h Holter monitoring was performed at 3
and 6 months, and every 6 months thereafter, according to the
latest guidelines (11). AF recurrence was defined as any episode
of AF or AT of at least 30 s in duration. Any ECG documentation
of an AF recurrence within the 3-month blanking period was
diagnosed as an early recurrence, and an AF recurrence of more
than 3 months after the AFCA was diagnosed as a clinical
recurrence.We evaluated the time point of the clinical recurrence
as follows: within 1 year as a short-term and beyond 1 year as
a long-term recurrence. We also estimated the quality of the
AF control after the AFCA. We defined patients with sustained
AF/AT as those who remained in a sustaining AF/AT rhythm
(>30 s) on the final follow-up after the AFCA despite AADs or
electrical cardioversion.
Statistical Analysis
The baseline characteristics of the patients were compared using
descriptive statistics and presented as median (interquartile
interval) values for continuous variables and as numbers
(percentages) for categorical variables. To compare the baseline
characteristics according to the baseline H2FPEF and the 1-year
change in the H2FPEF score (1H2FPEF score[1−yr]) categories,
the Mantel–Haenszel chi-squared test was used for categorical
variables, and the Kruskal–Wallis H test was used for continuous
variables. To identify the factors associated with the baseline
H2FPEF and 1H2FPEF score[1−yr], univariate and multivariable
logistic regression analyses were performed. Multivariable Cox
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TABLE 1 | Baseline characteristics according to the baseline H2FPEF score stratification in atrial fibrillation (AF) patients with a normal left ventricular ejection fraction
(LVEF).
Overall (N = 1,471) 3 score (N = 373) 4–5 score (N = 866) ≥6 score (N = 232) p-value
Age, years 60 (53, 68) 52 (46, 56) 63 (56, 69) 68 (63, 74) <0.001
Age over 65 years, n (%) 463 (31.5) 0 (0) 316 (36.5) 147 (63.4) <0.001
Female, n (%) 452 (30.7) 65 (17.4) 282 (32.6) 105 (45.3) <0.001
FU duration, months 56 (32, 87) 54 (31, 85) 58 (33, 89) 57 (33, 86) 0.232
BMI, kg/m2 24.6 (23.0, 26.6) 24.5 (23.0, 26.4) 24.4 (22.8, 26.4) 25.4 (23.6, 28.0) <0.001
Paroxysmal AF, n (%) 1,009 (68.6) 266 (71.3) 597 (68.9) 146 (62.9) 0.092
Smoking, n (%) 0.014
Never 957 (65.1) 232 (62.2) 555 (64.1) 170 (73.3)
Former/current 514 (34.9) 141 (37.8) 311 (35.9) 62 (26.7)
Alcohol, n (%) <0.001
Never 771 (52.4) 159 (42.6) 461 (53.2) 151 (65.1)
Former/current 700 (47.6) 214 (57.4) 405 (46.8) 81 (34.9)
CHA2DS2-VASc score 2 (1, 3) 0 (0, 1) 2 (1, 3) 3 (2, 4) <0.001
Heart failure, n (%)* 96 (6.5) 14 (3.8) 51 (5.9) 31 (13.4) <0.001
Hypertension, n (%) 714 (48.5) 54 (14.5) 450 (52.0) 210 (90.5) <0.001
Diabetes, n (%) 222 (15.1) 27 (7.2) 134 (15.5) 61 (26.3) <0.001
Prior stroke/TIA, n (%) 180 (12.2) 25 (6.7) 113 (13.0) 42 (18.1) 0.004
Vascular disease, n (%) 194 (13.2) 10 (2.7) 135 (15.6) 49 (21.1) <0.001
Hypertrophic cardiomyopathy, n (%) 36 (2.4) 1 (0.3) 28 (3.2) 7 (3.0) 0.007
Obstructive sleep apnea, n (%) 16 (1.1) 3 (0.8) 11 (1.3) 2 (0.9) 0.720
Chronic obstructive pulmonary disease, n (%) 21 (1.4) 2 (0.5) 14 (1.6) 5 (2.2) 0.202
Thyroid disease, n (%) 108 (7.3) 20 (5.4) 67 (7.7) 21 (9.1) 0.188
Laboratory
eGFR, ml/min/1.73 m2 80.3 (69.0, 92.9) 86.1 (75.3, 97.2) 79.5 (68.9, 92.1) 72.0 (59.4, 84.3) <0.001
hs-CRP, mg/dl 0.7 (0.5, 1.5) 0.7 (0.3, 1.3) 0.8 (0.5, 1.4) 1.0 (0.6, 2.1) <0.001
Echocardiography
LA diameter, mm 41 (37, 45) 39 (36, 42) 41 (37, 45) 44 (41, 48) <0.001
LAVI, ml/m2 35.0 (28.3, 43.0) 30.3 (25.8, 35.9) 35.6 (28.7, 43.4) 42.0 (35.0, 50.5) <0.001
LVEF, % 65 (60, 69) 63 (60, 68) 65 (61, 69) 65 (61, 70) 0.009
E/Em 9.2 (7.8, 12.0) 7.0 (6.0, 8.0) 10.0 (8.0, 12.0) 12.9 (11.0, 15.4) <0.001
E, m/s 0.7 (0.6, 0.8) 0.7 (0.6, 0.8) 0.7 (0.6, 0.8) 0.8 (0.6, 1.0) <0.001
Em, cm/s 7.0 (6.0, 9.0) 9.5 (8.0, 11.0) 7.0 (5.6, 8.7) 6.0 (5.0, 7.2) <0.001
TR jet, m/s 2.3 (2.1, 2.5) 2.1 (2.0, 2.3) 2.3 (2.1, 2.5) 2.5 (2.3, 2.8) <0.001
RVSP, mmHg 26 (22, 30) 24 (21, 27) 26 (23, 30) 30 (26, 37) <0.001
LVEDD, mm 50 (46, 53) 50 (47, 52) 50 (46, 52) 50 (46, 53) 0.412
LVESD, mm 33 (30, 36) 33 (31, 36) 33 (30, 35) 33 (30, 36) 0.140
LVMI, g/m2 90.9 (79.4, 102.9) 85.0 (75.8, 94.8) 91.3 (80.1, 104.4) 99.2 (87.9, 112.6) <0.001
3D-CT, ml
Pericardial fat volume 101.1 (70.8, 140.9) 91.2 (63.8, 135.3) 101.9 (70.9, 143.3) 113.8 (81.5, 156.1) <0.001
LA volume 147.3 (120.8, 178.2) 132.3 (113.4, 163.2) 149.0 (122.6, 177.9) 163.9 (140.4, 195.1) <0.001
Voltage, mV
LA mean voltage 1.3 (0.8, 1.8) 1.5 (1.0, 2.0) 1.3 (0.8, 1.7) 1.1 (0.7, 1.5) <0.001
LA pressure, mmHg
Peak 20 (15, 27) 20 (15, 25) 20 (15, 27) 22 (17, 29) 0.004
Nadir 4 (1, 8) 4 (1, 8) 5 (1, 8) 5 (1, 9) 0.348
Mean 11 (8, 16) 11 (7, 15) 11 (8, 16) 13 (9, 17) 0.006
Medication, n (%)
ACEi/ARB 493 (33.5) 33 (8.8) 293 (33.9) 167 (72.0) <0.001
Beta-blocker 487 (33.1) 104 (27.9) 274 (31.7) 109 (47.0) <0.001
(Continued)
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TABLE 1 | Continued
Overall (N = 1,471) 3 score (N = 373) 4–5 score (N = 866) ≥6 score (N = 232) p-value
Statin 491 (33.4) 57 (15.3) 322 (37.2) 112 (48.3) <0.001
AAD
†
200 (13.7) 40 (10.8) 118 (13.7) 42 (18.1) 0.038
Recurrence after AFCA, n (%)
Early recurrence 448 (30.5) 111 (29.8) 271 (31.3) 66 (28.4) 0.666
Clinical recurrence
1-year duration 257 (17.5) 62 (16.6) 152 (17.6) 43 (18.5) 0.830
Total duration 611 (41.5) 145 (38.9) 358 (41.3) 108 (46.6) 0.173
Sustained AF
1-year duration 56 (3.8) 16 (4.3) 28 (3.2) 12 (5.2) 0.333
Total duration 95 (6.5) 27 (7.2) 51 (5.9) 17 (7.3) 0.568
The data are presented as the number (%) and median (interquartile interval). Non-parametric continuous variables as assessed by the Kolmogorov–Smirnov method were analyzed
by the Mann–Whitney U-test. AAD, antiarrhythmic drug; ACEi, angiotensin-converting-enzyme inhibitor; AF, atrial fibrillation; AFCA, atrial fibrillation catheter ablation; ARB, angiotensin
receptor blocker; BMI, body mass index; E/Em, ratio of the early diastolic mitral inflow velocity (E) to the early diastolic mitral annular velocity (Em); FU, follow up; eGFR, estimated
glomerular filtration rate; hs-CRP, high sensitivity C-reactive protein; LA, left atrium; LVEDD, left ventricular end diastolic dimension; LVEF, left ventricular ejection fraction; LVESD, left
ventricular end systolic dimension; LVMI, left ventricular mass index; RVSP, right ventricular systolic pressure; TIA, transient ischemic attack; TR, tricuspid regurgitation. *Defined as
conventional HFpEF diagnosis riteria: left ventricular ejection fraction ≥50% with exertional dyspnea that was not caused by extracardiac causes.
†
Including class Ic and III drugs, taken
after catheter ablation.
proportional hazard analyses were performed to evaluate the
association of the baseline H2FPEF and 1H2FPEF score[1−yr]
with a clinical recurrence in both the short- and long-term
periods. A multivariable regression analysis included those
variables with significant p-values of <0.1 in the univariate
analysis. The Cox proportional hazards assumption was tested
based on Schoenfeld residuals. Two-sided p-values < 0.05 were
considered statistically significant. The statistical analyses were
conducted using SAS version 9.4 (SAS Institute) and R version
4.0.0 (R Foundation for Statistical Computing) software.
RESULTS
Characteristics of the Patients With High
H2FPEF Scores
Table 1 summarizes patient characteristics depending on the
H2FPEF score. In the 1,471 patients, the median (IQR) age was
60 (53, 68) years, 30.7% were female, and 68.6% had paroxysmal-
type AF. The baseline H2FPEF scores were 3 points in 373
patients (25.3%), 4–5 points in 866 (58.9%), and ≥6 points in
232 (15.8%) patients. Patients with higher H2FPEF scores were
older and had a higher body mass index, hypertension, estimated
RVSP, and higher E/Em, as those variables that composed
this score. In the higher H2FPEF score-group, the CHA2DS2-
VASc score (p < 0.001), prevalence of diabetes (p < 0.001),
a prior stroke (p = 0.004), vascular disease (p < 0.001), or
hypertrophic cardiomyopathy (p = 0.007) were higher. The
CT-measured LA volume (p < 0.001), pericardial fat volume
(p < 0.001), and LA peak pressure (p = 0.004) were higher,
and the endocardial bipolar LA voltage (p < 0.001) and eGFR
(p < 0.001) were significantly lower in the higher H2FPEF
score-group. In the multivariate logistic regression analysis
(Supplementary Table 1), high baseline H2FPEF scores (≥6)
were independently associated with the female sex [OR, 2.31
(1.35–3.93), p= 0.002], higher left atrial (LA) diameter [OR, 1.09
(1.04–1.13), p < 0.001], LV mass index [OR 1.02 (1.01–1.03), p=
0.002], pericardial fat volume [OR, 1.01 (1.00–1.01), p = 0.015],
and lower eGFR [OR, 0.98 (0.97–0.99), p < 0.001].
1H2FPEF Score[1-yr]
One year after the AFCA, the H2FPEF scores decreased in 17.1%
of the patients (252), were maintained in 61.5% (905), and
increased in 21.4% (314) (Table 2). A reduction in the 1H2FPEF
score[1−yr] was more commonly observed in patients with high
baseline H2FPEF scores (Figure 2A) and was independently
associated with baseline H2FPEF scores of ≥6 [OR, 4.19 (2.88–
6.11), p < 0.001], the absence of diabetes [OR, 0.60 (0.37–0.98),
p = 0.04], a higher LVEF [OR, 1.03 (1.01–1.06), p = 0.011], and
a lower pericardial fat volume [OR, 0.99 (0.99–1.00), p = 0.003;
Table 3]. Increased 1H2FPEF scores[1−yr] were less commonly
observed in patients with high H2FPEF scores (Figure 2B) and
were associated with a baseline H2FPEF score of <6 [OR, 3.54
(2.08–6.04), p < 0.001], sustained AF after a recurrence within a
year [SustainAF[1−yr]; OR, 1.89 (1.01–3.54), p = 0.048], the LA
volume [OR, 1.00 (1.00–1.01), p = 0.029], and the pericardial fat
volume [OR, 1.00 (1.00–1.01), p= 0.032; Table 4].
Rhythm Outcomes After Atrial Fibrillation
Catheter Ablation and the H2FPEF Score
Because we evaluated the H2FPEF score before and 1 year
after the procedure, we compared the 1-year and long-term
clinical recurrence rates of AF separately, depending on the
baseline H2FPEF scores and 1H2FPEF scores[1−yr]. In contrast,
the baseline H2FPEF scores did not affect the 1-year rhythm
outcome (log rank, p = 0.82; Figure 3A), and the clinical
recurrence of AF was significantly higher in the patients
with an increased 1H2FPEF scores[1−yr] (log rank, p =
0.003; Figure 3B). In the multivariate Cox regression analysis,
increased 1H2FPEF scores[1−yr] [HR, 2.34 (1.36–4.03), p =
0.002] and persistent AF [HR, 1.43 (1.01–2.03), p = 0.043]
Frontiers in Cardiovascular Medicine | www.frontiersin.org 5 August 2021 | Volume 8 | Article 699364
Kim et al. H2FPEF Score After AF Ablation
TABLE 2 | Baseline characteristics according to the change in the H2FPEF scores in AF patients with a normal LVEF, 1-year after the atrial fibrillation catheter ablation
(AFCA).
Decreased (−2, −1) (N = 252) Maintained (0) (N = 905) Increased (+1, +2, +3) (N = 314) p-value
Age, years* 62 (55, 68) 59 (52, 67) 60 (58, 68) <0.001
Age over 65 years, n (%) 82 (32.5) 272 (30.1) 109 (34.7) 0.286
v Female, n (%) 78 (31.0) 283 (31.3) 91 (29.0) 0.748
FU duration, months 53 (31, 88) 58 (32, 87) 58 (33, 89) 0.467
BMI, kg/m2 24.4 (22.8, 26.1) 24.6 (23.0, 26.7) 24.6 (23.2, 26.7) 0.445
Paroxysmal AF, n (%) 183 (72.6) 622 (68.7) 204 (65.0) 0.148
Smoking, n (%) 0.152
Never 157 (62.3) 606 (67.0) 194 (61.8)
Former/current, n (%) 95 (37.7) 299 (33.0) 120 (38.2)
Alcohol 0.222
Never 141 (56.0) 477 (52.7) 153 (48.7)
Former/current 111 (44.0) 428 (47.3) 161 (51.3)
CHA2DS2-VASc score 2 (1, 3) 1 (0, 3) 2 (1, 3) 0.238
Heart failure, n (%)
†
20 (7.9) 56 (6.2) 20 (6.4) 0.606
Hypertension, n (%) 133 (52.8) 431 (47.6) 150 (47.8) 0.335
Diabetes, n (%) 29 (11.5) 142 (15.7) 51 (16.2) 0.212
Prior stroke/TIA, n (%) 37 (14.7) 108 (11.9) 35 (11.1) 0.401
Vascular disease, n (%) 33 (13.1) 115 (12.7) 46 (14.6) 0.680
Hypertrophic cardiomyopathy, n (%) 11 (4.4%) 17 (1.9%) 8 (2.5%) 0.077
Obstructive sleep apnea, n (%) 2 (0.8) 12 (1.3) 2 (0.6) 0.529
Chronic obstructive pulmonary disease, n (%) 3 (1.2) 12 (1.3) 6 (1.9) 0.709
Thyroid disease, n (%) 16 (6.3) 68 (7.5) 24 (7.6) 0.800
Laboratory
eGFR, ml/min/1.73m2
80.3 (69.8, 91.4) 81.0 (69.4, 93.8) 79.0 (66.7, 90.7) 0.265
hs-CRP, mg/dl 0.8 (0.5, 1.4) 0.7 (0.5, 1.5) 0.8 (0.6, 1.8) 0.170
Echocardiography
LA diameter, mm
41 (38, 45) 41 (37, 45) 41 (37, 46) 0.264
LAVI, ml/m2 36.2 (29.4, 44.3) 34.5 (27.7, 42.7) 35.5 (28.4, 43.6) 0.134
LVEF, % 66 (62, 70) 64 (60, 69) 65 (60, 69) 0.005
E/Em, 11.0 (10.0, 13.0) 9.0 (7.0, 12.0) 8.4 (7.3, 9.0) <0.001
E, m/s 0.8 (0.6, 0.9) 0.7 (0.6, 0.8) 0.7 (0.6, 0.8) <0.001
Em, cm/s 6.3 (5.0, 8.0) 7.5 (6.0, 9.3) 8.0 (6.0, 9.0) <0.001
TR jet, m/s 2.4 (2.1, 2.7) 2.2 (2.1, 2.4) 2.3 (2.1, 2.4) <0.001
RVSP, mmHg 28 (23, 36) 25 (22, 29) 26 (22, 29) <0.001
LVEDD, mm 50 (46, 53) 50 (47, 53) 49 (46, 52) 0.309
LVESD, mm 33 (30, 36) 33 (30, 36) 33 (31, 35) 0.285
LVMI, g/m2 92.9 (80.5, 107.1) 90.1 (79.4, 102.3) 91.6 (79.2, 102.3) 0.223
3D-CT, ml
Pericardial fat volume
96.8 (63.8, 134.1) 100.9 (71.0, 140.6) 108.4 (78.3, 150.3) 0.012
LA volume 144.0 (121.2, 174.2) 146.9 (119.8, 176.6) 152.7 (124.2, 184.1) 0.084
Voltage, mV
LA mean voltage
1.4 (0.9, 1.8) 1.3 (0.9, 1.8) 1.3 (0.8, 1.7) 0.277
LA pressure, mmHg
Peak
20 (15, 27) 20 (15, 27) 21 (16, 27) 0.394
Nadir 5 (1, 9) 4 (1, 8) 5 (1, 8) 0.681
Mean 11 (8, 16) 11 (8, 16) 12 (8, 16) 0.333
1-year change in the Echocardiography, 1
1 LA diameter, mm
−4 (−6, −1) −3 (−5, 0) −2 (−5, 1) <0.001
1 LAVI, ml/m2 −8.0 (−14.0, −2.3) −5.2 (−10.7, −0.2) −3.6 (−9.1, 1.9) <0.001
1 LVEF, % 1 (−4, 5) 1 (−3, 6) 1 (−3, 5) 0.459
1 E/Em −3.0 (−4.2, −1.4) 0 (−1.1, 1.5) 2.8 (1.0, 4.4) <0.001
1 E, m/s −0.1 (−0.2, 0) 0 (−0.2, 0) 0 (−0.1, 0.1) <0.001
1 Em, cm/s 0.9 (-1.0, 2.0) −0.8 (−2.0, 0.5) −1.4 (-3.0, 0) <0.001
1 TR jet, m/s −0.1 (−0.4, 0) 0 (−0.2, 0.2) 0.1 (−0.1, 0.4) <0.001
1 RVSP, mmHg −3 (−9, 0) −1 (−4, 3) 2.2 (−3, 8) <0.001
1 LVEDD, mm −1 (−3, 1) 0 (−2, 2) 0 (−2, 2) <0.001
1 LVESD, mm −1 (−3, 1) −1 (−3, 1) 0 (−2, 2) 0.007
1 LVMI, g/m2 −2.8 (−13.9, 5.6) 1.0 (−9.4, 9.4) 3.3 (−8.8, 13.1) <0.001
(Continued)
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TABLE 2 | Continued
Decreased (−2, −1) (N = 252) Maintained (0) (N = 905) Increased (+1, +2, +3) (N = 314) p-value
Medication, n (%)
ACEi/ARB
96 (38.1) 298 (33.0) 99 (31.5) 0.218
Beta-blocker 93 (36.9) 285 (31.5) 109 (34.7) 0.220
Statin 96 (38.1) 289 (32.0) 106 (33.8) 0.188
AAD
‡
30 (12.0) 118 (13.1) 52 (16.6) 0.204
Recurrence after the AFCA, n (%)
Early recurrence
68 (27.0) 281 (31.0) 99 (31.5) 0.416
Clinical recurrence
1-year duration
33 (13.1) 151 (16.7) 73 (23.2) 0.004
Total duration 99 (39.3) 361 (39.9) 151 (48.1) 0.029
Sustained AF
1-year duration
6 (2.4) 32 (3.5) 18 (5.7) 0.093
Total duration 14 (5.6) 59 (6.5) 22 (7.0) 0.774
The data are presented as the number (%) and median (interquartile interval). Non-parametric continuous variables as assessed by the Kolmogorov–Smirnov method, were analyzed
by the Mann–Whitney U-test. AAD, antiarrhythmic drug; ACEi, angiotensin-converting-enzyme inhibitor; AF, atrial fibrillation; AFCA, atrial fibrillation catheter ablation; ARB, angiotensin
receptor blocker; BMI, body mass index; EEm, ratio of the early diastolic mitral inflow velocity (E) to the early diastolic mitral annular velocity (Em); FU, follow up; eGFR, estimated
glomerular filtration rate; hs-CRP, high sensitivity C-reactive protein; LA, left atrium; LVEDD, left ventricular end diastolic dimension; LVEF, left ventricular ejection fraction; LVESD, left
ventricular end systolic dimension; LVMI, left ventricular mass index; RVSP, right ventricular systolic pressure; TIA, transient ischemic attack; TR, tricuspid regurgitation. * Increased vs.
maintained, p < 0.001; increased vs. decreased, p = 0.263; maintained vs. decreased, p = 0.105.
†
Defined as conventional HFpEF diagnosis criteria: left ventricular ejection fraction
≥50% with exertional dyspnea that was not caused by extracardiac causes.
‡
Including class Ic and III drugs, taken after catheter ablation.
FIGURE 2 | Change in the 1-year H2FPEF scores after the AFCA, according to the baseline H2FPEF scores (A, B) and rhythm outcomes within a year C, D). AF, atrial
fibrillation; AFCA, atrial fibrillation catheter ablation.
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TABLE 3 | Logistic regression analysis for predictors of decreased H2FPEF scores, 1-year after the AFCA.
Univariate analysis Multivariable analysis
Unadjusted HR (95% CI) p-value Adjusted HR (95% CI) p-value
Baseline H2FPEF scores
<6 score (reference) 1.00 (reference) 1.00 (reference)
≥6 score 3.81 (2.79–5.21) <0.001 4.19 (2.88–6.11) <0.001
Age 1.01 (0.99–1.02) 0.285
Female 1.01 (0.76–1.36) 0.932
Paroxysmal AF 1.26 (0.93–1.70) 0.135
Body mass index 0.98 (0.94–1.03) 0.484
Smoking 1.16 (0.87–1.53) 0.314
Alcohol 0.84 (0.64–1.11) 0.217
Heart failure* 1.30 (0.78–2.16) 0.321
Hypertension 1.23 (0.94–1.61) 0.139
Diabetes 0.69 (0.46–1.05) 0.082 0.60 (0.37–0.98) 0.040
Prior stroke/TIA 1.29 (0.88–1.91) 0.194
Vascular disease 0.99 (0.66–1.48) 0.962
CHA2DS2-VASc score 1.05 (0.96–1.14) 0.306
LA diameter 1.00 (0.98–1.03) 0.708
LVEF 1.04 (1.01–1.06) 0.002 1.03 (1.01–1.06) 0.011
E/Em 1.13 (1.09–1.66) <0.001
TR jet velocity 1.16 (0.98–1.36) 0.077
RVSP 1.09 (1.06–1.11) <0.001
LVEDD 1.01 (0.98–1.05) 0.412
LVESD 0.97 (0.94–1.01) 0.145
LVMI 1.01 (1.00–1.01) 0.062 1.00 (0.99–1.01) 0.708
eGFR 1.00 (0.99–1.01) 0.745
hs-CRP 1.00 (0.99–1.00) 0.665
Pericardial fat volume 1.00 (1.00–1.00) 0.087 0.99 (0.99–1.00) 0.003
LA volume 1.00 (0.99–1.01) 0.540
LA mean voltage 1.03 (0.81–1.30) 0.825
LA peak pressure 0.99 (0.97–1.01) 0.166
Sustained AF
†
1-year duration 0.57 (0.24–1.35) 0.199
Total duration 0.83 (0.46–1.48) 0.522
AF, atrial fibrillation; AFCA, atrial fibrillation catheter ablation; BMI, body mass index; EEm, ratio of the early diastolic mitral inflow velocity (E) to the early diastolic mitral annular velocity
(Em); eGFR, estimated glomerular filtration rate; hs-CRP, high sensitivity C-reactive protein; LA, left atrium; LVEDD, left ventricular end diastolic dimension; LVEF, left ventricular ejection
fraction; LVESD, left ventricular end systolic dimension; LVMI, left ventricular mass index; RVSP, right ventricular systolic pressure; TIA, transient ischemic attack; TR, tricuspid regurgitation.
*Defined as conventional HFpEF diagnosis criteria: left ventricular ejection fraction ≥50% with exertional dyspnea that was not caused by extracardiac causes.
†
Defined as patients who
remained in a sustained AF rhythm (>30 s) on the final follow-up date despite antiarrhythmic drugs or electrical cardioversion.
were independently associated with an AF recurrence within
a year (Supplementary Table 2). During the median follow-
up of 56 (32, 87) months, increased 1H2FPEF scores[1−yr]
[HR, 1.41 (1.01–1.98), p = 0.045], the LA diameter [HR,
1.03 (1.01–1.06), p = 0.002], and the LA voltage [HR, 0.59
(0.48–0.73), p < 0.001] were independently associated with a
long-term AF recurrence (Table 5). The rhythm outcomes in
the overall duration were consistent with the 1-year rhythm
outcome depending on the baseline H2FPEF score (log rank,
p = 0.57; Figure 3C) or 1H2FPEF score[1−yr] (log rank, p =
0.01; Figure 3D). In the subgroup of patients with baseline
H2FPEF scores of ≥5, the risk of an AF recurrence was
significantly higher in the patients with increased 1H2FPEF
scores[1−yr] than in those with reduced 1H2FPEF scores[1−yr]
(Supplementary Figure 1).
Failed Rhythm Control and the 1H2FPEF
Score[1-yr]
Among the 1,471 patients, 257 (17.5%) had an AF recurrence
within a year, and 201 (13.7%) had sinus rhythm restored after
using antiarrhythmic drugs, but 56 (3.8%) patients had sustained
AF under antiarrhythmic drugs even after cardioversion. The
proportion of patients with reduced 1H2FPEF scores[1−yr]
tended to be higher without a statistical significance among
those with no recurrence (p = 0.118, Figure 2C). However,
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TABLE 4 | Logistic regression analysis for predictors of increased H2FPEF scores, 1-year after the AFCA.
Univariate analysis Multivariable analysis
Unadjusted OR (95% CI) p-value Adjusted OR (95% CI) p-value
Baseline H2FPEF scores
<6 score 1.14 (0.89–1.46) 0.311 3.54 (2.08–6.04) <0.001
≥6 score (reference) 1.00 (reference) 1.00 (reference)
Age 1.03 (1.01–1.04) <0.001
Female 0.90 (0.68–1.18) 0.450
Paroxysmal AF 0.81 (0.62–1.05) 0.114
Body mass index 1.02 (0.98–1.07) 0.323
Smoking 1.20 (0.93–1.55) 0.170
Alcohol 1.21 (0.94–1.55) 0.140
CHA2DS2-VASc score 1.00 (0.92–1.08) 0.965
Heart failure* 0.97 (0.58–1.61) 0.899
Hypertension 0.96 (0.75–1.23) 0.759
Diabetes 1.12 (0.80–1.57) 0.521
Prior stroke/TIA 0.88 (0.59–1.30) 0.507
Vascular disease 1.17 (0.82–1.67) 0.389
LA diameter 1.02 (0.99–1.04) 0.168
LVEF 1.00 (0.98–1.02) 0.813
E/Em 0.89 (0.86–0.93) <0.001
TR jet velocity 0.81 (0.56–1.18) 0.276
RVSP 0.98 (0.96–1.00) 0.071
LVEDD 0.98 (0.95–1.01) 0.271
LVESD 0.99 (0.96–1.02) 0.484
LVMI 1.00 (0.99–1.01) 0.595
eGFR 1.00 (0.99–1.00) 0.122
hs-CRP 0.99 (0.97–1.02) 0.435
Pericardial fat volume 1.00 (1.00–1.01) 0.012 1.00 (1.00–1.01) 0.032
LA volume 1.00 (1.00–1.01) 0.023 1.00 (1.00–1.01) 0.029
LA mean voltage 0.84 (0.67–1.05) 0.126
LA peak pressure 1.01 (0.99–1.02) 0.405
Sustained AF
†
1-year duration 1.79 (1.01–3.18) 0.047 1.89 (1.01–3.54) 0.048
Total duration 1.12 (0.68–1.83) 0.656
AF, atrial fibrillation; AFCA, atrial fibrillation catheter ablation; BMI, body mass index; EEm, ratio of the early diastolic mitral inflow velocity (E) to the early diastolic mitral annular velocity
(Em); eGFR, estimated glomerular filtration rate; hs-CRP, high sensitivity C-reactive protein; LA, left atrium; LVEDD, left ventricular end diastolic dimension; LVEF, left ventricular ejection
fraction; LVESD, left ventricular end systolic dimension; LVMI, left ventricular mass index; RVSP, right ventricular systolic pressure; TIA, transient ischemic attack; TR, tricuspid regurgitation.
*Defined as conventional HFpEF diagnosis criteria: left ventricular ejection fraction ≥50% with exertional dyspnea that was not caused by extracardiac causes.
†
Defined as patients who
remained in a sustained AF rhythm (>30 sec) on the final follow-up date despite antiarrhythmic drugs or electrical cardioversion.
the proportion of patients with increased 1H2FPEF scores[1−yr]
was significantly higher in the group with sustained AF after a
recurrence than in those with sinus rhythm maintained at a year
after the AFCA (p= 0.007, Figure 2D).
DISCUSSION
Main Findings
In this study, we observed a change in the H2FPEF score 1 year
after the AFCA in AF patients with a normal LV systolic function.
The H2FPEF score[1−yr] decreased in 17% of the patients but
increased in 21% a year after the AFCA. A high baseline
H2FPEF score, which is related to LV diastolic dysfunction, was
independently associated with a reduced 1H2FPEF score[1−yr].
On the other hand, low baseline scores or sustained AF after a
recurrence were significantly associated with an increase in the
1H2FPEF scores[1−yr] after the AFCA. Patients with an increased
1H2FPEF score[1−yr] had higher rates of recurrence within a year
or longer. Therefore, AFCA improved the H2FPEF scores[1−yr] in
patients with baseline LV diastolic dysfunction; however, patients
with a poor rhythm control and sustained AF despite AFCA had
a significant increase in the 1H2FPEF scores[1−yr].
Atrial Fibrillation and the Ventricular
Diastolic Function
AF and LV diastolic dysfunction are closely related and
have important features in common, such as age, obesity,
hypertension, and diabetes (19). LV diastolic dysfunction has
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FIGURE 3 | Rate of the freedom from an AF recurrence over 1-year (A, B) and during the long-term (C, D) after the AFCA based on the baseline H2FPEF scores and
changes in the 1-year H2FPEF scores.
deteriorative effects on the atrial function and structure, which
contributes to the development, progression, and maintenance
of AF (20). Consequently, AF has an influence on the LV
function and LA remodeling (21), and can lead to increasingly
sustained AF episodes. Therefore, these two conditions have
pathophysiological effects on the occurrence and aggravation
of each, and coexistence is associated with a poor prognosis
(2, 22, 23). Furthermore, as the AF burden increases chronically,
the right ventricular function progressively worsens (24). Reddy
et al. (10) proposed a novel risk score, the H2FPEF score, which
includes all of the abovementioned factors, to diagnose HFpEF
patients. We adopted this score to evaluate the prognostic utility
in AF patients with a normal LVEF after AFCA.
Effects of Atrial Fibrillation Catheter
Ablation on the Left Venticular Diastolic
Function
The data to support the clinical benefits of catheter ablation in
symptomatic AF patients with HFrEF are strong and compatible
with those from previous clinical trials and meta-analyses (6,
25). However, AF is more potently associated with HFpEF
(2) with the prevalence of HFpEF increasing by almost half
in AF patients (26). The benefits of AFCA in symptomatic
AF patients with HFpEF have been investigated in previous
studies (7, 8), but the effects seem less favorable than those in
HFrEF patients. Machino-Ohtsuka et al. (7) showed that the
longstanding persistent-type AF and a lack of hypertension were
factors associated with an improvement in the LV systolic and
diastolic indices when sinus rhythm was maintained. Black-
Maier et al. (8) showed equivalent rhythm outcomes, all-cause
hospitalization, and cardiovascular hospitalization in patients
with both HFpEF and HFrEF after AFCA over a median
follow-up of 10 months. However, previous studies adopted
conventional diagnostic approaches that mainly consisted of
symptoms and the LVEF for an HFpEF diagnosis, which show
a heterogeneity in terms of the inclusion (9). Thus, we used
the H2FPEF scores that were newly developed for identifying
HFpEF patients and which were superior to the previous
diagnostic algorithms. Although the baseline H2FPEF scores do
not have prognostic value for rhythm outcomes after AFCA,
which is consistent with a recent study (27), increased 1H2FPEF
scores[1−yr] were independently associated with the rhythm
outcomes in this study. Although the cause–result relationship
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TABLE 5 | Cox regression analysis of the predictors of an AF recurrence after the AFCA, during the long-term follow up.
Univariable analysis Multivariable analysis
Unadjusted HR (95% CI) p-value Adjusted HR (95% CI) p-value
Baseline H2FPEF scores 1.03 (0.96–1.11) 0.421
Baseline H2FPEF scores
3 score (reference) 1.00
4–5 score 1.03 (0.85–1.25) 0.757
≥6 score 1.14 (0.89–1.46) 0.311
Change in H2FPEF scores, 1 year 1.20 (1.07–1.35) 0.002
Change in H2FPEF scores, 1-year
Decreased, <0 (reference) 1.00 1.00
Maintained, 0 1.06 (0.85–1.32) 0.611 1.06 (0.78–1.44) 0.699
Increased, >0 1.38 (1.07–1.78) 0.012 1.41 (1.01–1.98) 0.045
Age 1.00 (1.00–1.01) 0.460
Female 1.09 (0.92–1.29) 0.307 1.05 (0.82–1.34) 0.694
Persistent AF 1.71 (1.62–2.24) <0.001 1.19 (0.93–1.53) 0.163
Body mass index 1.03 (1.00–1.06) 0.038
Smoking 1.04 (0.86–1.20) 0.821
Alcohol 0.95 (0.81–1.12) 0.547
CHA2DS2-VASc score 1.03 (0.98–1.08) 0.221
Heart failure* 1.43 (1.06–1.93) 0.929
Hypertension 1.14 (0.89–1.46) 0.019
Diabetes 1.00 (0.80–1.25) 0.973
Prior stroke/TIA 1.06 (0.84–1.34) 0.640
Vascular disease 1.05 (0.84–1.31) 0.667
LA diameter 1.05 (1.04–1.06) <0.001 1.03 (1.01–1.06) 0.002
LVEF 0.99 (0.97–1.00) 0.024 0.99 (0.97–1.01) 0.203
E/Em 1.00 (0.99–1.02) 0.629
TR jet velocity 1.01 (0.94–1.09) 0.751
RVSP 1.02 (1.01–1.03) <0.001
LVEDD 1.01 (1.00–1.03) 0.183
LVESD 1.02 (1.00–1.04) 0.101
LVMI 1.00 (1.00–1.01) 0.019 1.00 (0.99–1.01) 0.998
eGFR 1.00 (0.99–1.00) 0.380
hs-CRP 1.00 (0.99–1.01) 0.769
Pericardial fat volume 1.00 (1.00–1.00) 0.052 1.00 (1.00–1.00) 0.678
LA volume 1.01 (1.01–1.01) <0.001
LA mean voltage 0.56 (0.48–0.66) <0.001 0.59 (0.48–0.73) <0.001
LA peak pressure 1.01 (1.00–1.02) 0.010 0.99 (0.98–1.01) 0.304
AF, atrial fibrillation; AFCA, atrial fibrillation catheter ablation; BMI, body mass index; EEm, ratio of the early diastolic mitral inflow velocity (E) to the early diastolic mitral annular velocity
(Em); eGFR, estimated glomerular filtration rate; hs-CRP, high sensitivity C-reactive protein; LA, left atrium; LVEDD, left ventricular end diastolic dimension; LVEF, left ventricular ejection
fraction; LVESD, left ventricular end systolic dimension; LVMI, left ventricular mass index; RVSP, right ventricular systolic pressure; TIA, transient ischemic attack; TR, tricuspid regurgitation.
*Defined as conventional HFpEF diagnosis criteria: left ventricular ejection fraction ≥50% with exertional dyspnea that was not caused by extracardiac causes.
was unclear, sustained AF despite AFCA had a significant
correlation with an increased 1H2FPEF score[1−yr].
Heart Failure With Preserved Ejection
Fraction, a Good Candidate for Atrial
Fibrillation Catheter Ablation
Among the patients with a normal LV systolic function, which
subgroup is the most helpful based on the H2FPEF scores after
AFCA? Those with themost significant decrease in the1H2FPEF
scores[1−yr] were those with a baseline HFpEF score of ≥6, i.e.,
successful rhythm control by AFCA can significantly improve the
LV diastolic function in patients with HFpEF. Furthermore, the
absence of diabetes, a higher LVEF, and a lower pericardial fat
volume were associated with decreased 1H2FPEF scores[1−yr],
which suggested that metabolic factors may have influenced the
recovery of the LV diastolic function.
Limitations
This study had several limitations. First, since the current study
was conducted in a single center and included a relatively
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small number of patients, the findings cannot be generalized
to all patients with a normal LV systolic function. However,
there was also an advantage of this single-center cohort in that
the ablation and rhythm follow-up protocols were consistent.
Second, although we performed a regular rhythm follow-
up in all included patients, the exact AF burden could not
be assessed by the Holter monitoring. Third, we excluded
patients who did not have both baseline and 1-year follow-
up echocardiograms with all parameters taken from the same
institute, to calculate appropriate H2FPEF scores. Fourth, there
was some discrepancy between the HF clinically judged by the
CH2A2DS-VASc and H2FPEF scores because the clinical HF was
classified mainly by the LV systolic function. Finally, because
of the limited follow-up duration, we could not determine the
long-term changes in the biventricular function and other clinical
outcomes in this study. Future prospective and controlled studies
are warranted.
CONCLUSION
The H2FPEF scores decreased in 17% and increased in
21% of the patients with a normal LV function at 1
year after the AFCA. AFCA has shown a tendency to
improve the H2FPEF scores[1−yr] in the patients with
an abnormal diastolic function. However, a poor rhythm
control and sustained AF after the AFCA were significantly
associated with an increase in the 1H2FPEF score[1−yr].
An increased 1H2FPEF score[1−yr] was an independent
prognostic factor for poorer rhythm outcomes after
the AFCA.
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